Full Press Release Details
Quanterix Appoints Masoud Toloue as President
of Quanterix and Diagnostics
Toloue brings deep expertise and industry acumen
to lead the Company's strategic expansion into diagnostics
Billerica, Mass. - May 11, 2021 - Quanterix
Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision
health, today announced it has named Masoud Toloue to the position of President of Quanterix and Diagnostics, effective June 9, 2021.
"We are excited to welcome Masoud to our team at such an important
moment for Quanterix," said Kevin Hrusovsky, Chairman and Chief Executive Officer Quanterix. "We are making important
strides in advancing our diagnostic capability and assays, given the NIH RADx funding, our COVID-19 Emergency Use Authorizations and advances
in our neurology suite of assays for Multiple Sclerosis, Alzheimer's and Parkinson's research as well as phase III drug trials.
Masoud's strong growth track record of doubling PerkinElmer's diagnostics franchise, wealth of experience, deep roots in the
life sciences and business acumen will be instrumental as we continue implementing our value creation strategy of entering phase III drug
trials with leading protein biomarkers, such as Neurofilament Light (Nf-L), Phosphorylated Tau, Amyloid Beta 40 / 42, GFAP and others,
that we believe will ultimately have productive diagnostic and health screen utility in the fields of infectious disease, neurology and
Toloue brings a wealth of industry experience and high growth track
record to Quanterix. He joins Quanterix from PerkinElmer, where he most recently served as senior vice president, diagnostics. He previously
led that company's applied genomics business. Prior to this role, he founded and led Bioo Scientific's next generation sequencing
business which was acquired by PerkinElmer in 2016. He also co-founded and led Genohub, where he transformed that company from a supplier
of next generation sequencing matching technology to a leading platform provider for manging sequencing projects globally. He holds a
doctoral degree in molecular cell biology from the University at Buffalo and was a postdoctoral fellow in biochemistry at The University
of Texas Health Science Center at San Antonio.
In his new role, Toloue will oversee Quanterix' growing diagnostics
(Dx) business and assume responsibility for the Company's Accelerator Lab Services, strategic partnerships and corporate development.
"Quanterix is empowering a truly innovative approach to highly-sensitive
diagnostics that has incredible potential to change the way healthcare in administered," said Toloue. "I am eager to roll
up my sleeves and join this exceptional leadership team to support the company's continued diagnostics expansion."
To learn more about Quanterix,
visit www.quanterix.com/about.
Quanterix is a company that's digitizing biomarker analysis
with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential to
change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to
disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods
to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research
applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company
was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will,"
"expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well
as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based on Quanterix' expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix'
actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix'
filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except
as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Staci Didner, (407) 734-7325